Award a research and development small business technology transfer program phase II enhancement award to coalesenz, INC for project titled, point of care blood coagulopathy diagnosis.
Ended Definitive Contract Awarded Last action
- Contract number
- HT942525CE002
- Awardee
-
Coalesenz Inc. UEI J2FNAFKMP664
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $549,959
Award facts
- Opportunity
-
- HQ003420RBDST Solicitation number
- Contract value 100% obligated
- $549,958.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Cambridge, MA 02138, USA
- Research
- STTR Phase II
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a $549,958.78 Firm Fixed Price Small Business Technology Transfer (STTR) Phase II Enhancement contract to Coalesenz Inc., a woman-owned small disadvantaged business, for the development of point-of-care blood coagulopathy diagnostic technology. This award, made on July 28, 2025, is designated as a total small business set-aside and represents a continuation of the agency's investment in Coalesenz's innovative hemostasis profiling capabilities. The contract extends through August 27, 2026, with performance taking place in Cambridge, Massachusetts. The Phase II enhancement builds upon previous federal investments in the company's research and development efforts, including a prior STTR Phase II award from the Department of the Army Medical Command valued at approximately $1.1 million.
Coalesenz's point-of-care blood coagulopathy diagnostic technology has direct applications to military medicine and combat casualty care, enabling rapid assessment of bleeding risk in field and clinical settings. The company's iCoagLab hemostasis profiler represents a portable, hand-sized diagnostic tool designed to support critical medical decision-making in austere and advanced medical environments. This Phase II enhancement award reflects the Defense Health Agency's confidence in Coalesenz's ability to advance technologies that address critical gaps in combat casualty care and provide potential utility across civilian applications, including mechanical circulatory support and cardiac care scenarios.
Quick answers
Who was awarded contract HT942525CE002?
HT942525CE002 was awarded to Coalesenz Inc. by Defense Health Agency (Department of Defense) on July 28, 2025.
How much is contract HT942525CE002 worth?
The government has obligated $549,959 on HT942525CE002.
Was contract HT942525CE002 competed?
The extent of competition for HT942525CE002 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award